Figure 2.

Liver- and blood-stage parasite development after a single RAS or CPS immunization. (A) Visualization of in vivo parasite liver load 42 h after i.v. challenge with 10³ luciferase-expressing Pb ANKA SPZ in previously CQ-CPS (n = 8) or CQ-RAS (n = 8) immunized mice versus CQ treated (n = 8) control animals. (B) A single CQ-RAS but not CQ-CPS immunization resulted in reduced parasite liver load in comparison to CQ-treated control mice at 42 h after i.v. challenge with 10³ luciferase-expressing Pb ANKA SPZ (*P < 0.05; **P < 0.01, Tukey’s multiple comparisons test, 1-way ANOVA). (C) CQ-RAS (n = 7, one mouse who did not develop parasitemia was excluded from the analysis) and CQ-CPS (n = 8) immunization resulted in significantly impaired blood-stage development on days 6 to 8 post challenge with 10³ Pb ANKA SPZ i.v. in comparison to CQ-treated (n = 8) control mice (**P < 0.01, repeated measures ANOVA. Within the model, parasitemia on days 6, 7 and 8 after challenge were set as depended variables and analyzed with the covariate of d5 parasitemia).